AOP Orphan announces three-year results on Ropeginterferon alfa-2b in Polycythemia Vera at ASH
Vienna (pts046/03.12.2018/19:30) – * High rates of durable hematological response and symptom control with good tolerability were reconfirmed with Ropeginterferon alfa-2b after 36 months of treatment. * Disease Modification by Ropeginterferon alfa-2b was illustrated by high molecular response rates, associated with the ability to reduce allelic burden of both mutant JAK2 and importantly also non-JAK2 … Skaityti toliau